Introduction
Typical hemolytic uremic syndrome (HUS) is associated with gastrointestinal infections caused by Shiga toxin (Stx)-producing bacteria such as enterohemorrhagic Escherichia coli (EHEC), of which E. coli O157:H7 is the most common clinical isolate. 1 HUS is characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The renal glomerular lesion, termed thrombotic microangiopathy, features microthrombi in the capillaries leading to their occlusion and profound endothelial injury. 2 Thrombocytopenia is presumably secondary to platelet consumption in microthrombi along the damaged endothelial wall. 3, 4 Gastrointestinal infection with EHEC may result in diarrhea or hemorrhagic colitis followed in severe cases by HUS. 1 Although the bacteria are non-invasive 5 virulence factors gain access to the circulation after passing the intestinal barrier, and are thus presumed to reach the kidney during HUS. 6 Both Stx and E. coli O157:H7 lipopolysaccharide (O157LPS) have been detected in the circulation bound to platelets, monocytes and neutrophils. 7, 8 Stx is a bipartite molecule composed of a pentamer of B subunits which bind to the globotriaosylceramide (Gb3) receptor and an enzymatically active A subunit. The A subunit inhibits eukaryotic cell protein synthesis. 9 Both Stx and O157LPS have been shown to activate platelets, monocytes and neutrophils. 7 O157LPS binds to and activates platelets directly via toll-like receptor 4 (TLR-4) in complex with CD62 (P-selectin) 10 and Stx binds to pre-activated platelets. 3, 11 Binding of the B subunit of Stx1 (Stx1B) alone induces platelet activation. 3 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Stx and O157LPS induce the formation of platelet-leukocyte complexes in whole blood. 7 These complexes formed mainly between platelets and monocytes and expressed tissue factor, particularly under conditions of high shear stress. Tissue factor was also detected on microparticles released from these blood cells. 7 These in vitro findings were confirmed in whole blood from HUS patients 7 and suggested that platelet-leukocyte complexes, and microparticles derived thereof, could contribute to the prothrombotic state occurring during HUS.
In the current study we investigated if complement was activated on blood cell complexes and on the surface of blood cell-derived microparticles in Stx-associated HUS. Activation of platelets, neutrophils and monocytes is accompanied by complement deposition. [12] [13] [14] Complement activation on the surface of platelets and leukocytes is followed by the formation of the membrane-attack complex (MAC) C5b-9. 15, 16 In addition to its lytic capacity, the MAC may induce cell activation and proliferation, as previously reviewed. 17 Deposition of C5b-9
on platelets leads to release of microparticles. 18 Microparticles, released from platelets and monocytes during complement deposition, may partake in a prothrombotic state when they are coated with tissue factor as previously shown in atypical HUS mediated by factor H mutations. 15 The aim of this study was to investigate if complement was deposited on platelet-leukocyte complexes and microparticles-derived from these cells during Stx-associated HUS and if Stx and O157LPS could induce complement deposition contributing to the inflammatory and prothrombotic mechanisms of this disease.
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Materials and methods

Subjects
Blood samples were available from 12 patients (Table 1 diagnosed with EHEC-associated HUS and treated at the Department of Pediatrics, Lund University Hospital. There were 8 boys and 4 girls aged 1-11 years (median age 3 years). Patient samples were taken within three days (median 4 h) of admission while the children still had clinical signs of HUS. HUS was defined as hemolytic anemia (hemoglobin levels <100 g/L), thrombocytopenia (platelet counts <140 x 10 9 /L), and acute renal failure. Blood was also obtained from the children two to nine months after recovery. EHEC infection was detected as previously described 19 . Blood samples were also available from six pediatric controls, 3 girls and 3 boys, aged 1-15 years (median 9.5 years). These children were seen at the out-patient clinic of the Department of Pediatrics, Lund University Hospital, for unrelated conditions such as reflux nephropathy, immune deficiency or metabolic disorders and did not have a history of HUS or diarrhea at the time of sampling. Whole blood was available from five of these pediatric controls and plasma was available from all. Blood samples were also obtained from three patients with acute renal failure without any history of HUS or diarrhea at the time of blood sampling.
These patients were seen at the Department of Pediatrics, Lund University Hospital, for acute myeloid leukemia (a boy 13 years old) or at the Department of Nephrology, Lund University
Hospital for acute renal failure associated with hypertension and sepsis (an adult woman and man). Blood was also obtained from 12 healthy adult volunteers (7 women, 5 men) not using any medications. Samples from patients, controls and healthy donors were taken with the informed written consent of the subjects or their parents in accordance with the Declaration of Helsinki. The study was performed with the approval of the Ethics Committee of the Medical Faculty, Lund University.
Blood collection
Whole blood from patients and controls was drawn by venipuncture into vacutainer tubes 
Isolation of microparticles
Microparticles were isolated from patient whole blood or from whole blood stimulated with or without agonists (Stx2, Stx1, Stx1B or LPS). Platelet-free plasma was obtained from whole blood by an initial centrifugation step at 2600 x g for 15 min followed by a 5 min centrifugation at 9900 x g at rt to remove larger apoptotic bodies. Microparticles were washed twice in Hank's Balanced Salt Solution without Ca 
Characterization of C3 or C9 on platelets and platelet-derived microparticles
Platelet-rich-plasma was obtained from whole-blood, diluted 1:2 in RPMI 1640 and incubated with Stx2 (2.8 x 10 -9 M) or O157LPS (0.5 µg/mL) or left unstimulated for 40 min at 37ºC
followed by centrifugation at 2000 x g for 10 min to isolate platelets which were washed once in PBS. Likewise, platelet-derived microparticles were prepared from whole blood stimulated with Stx2 or O157LPS and isolated as described above. Platelets or platelet-derived microparticles were incubated with a combination of mouse anti- 
Isolation of neutrophils
Neutrophils were isolated under LPS-free conditions from citrated peripheral blood collected from healthy donors using one-step density gradient centrifugation with Polymorphprep® (Nycomed. Oslo, Norway), followed by hypotonic lysis of erythrocytes. Lysis was stopped by addition of x10 PBS (6:1). Neutrophils were washed twice in PBS and resuspended in RPMI-1640 with GlutaMax (Invitrogen), resulting in a suspension consisting of ~96% neutrophils as determined by flow cytometry using mouse anti-human CD66:RPE antibody. 
Flow cytometry acquisition and interpretation of data
Whole blood samples were lyzed with FACSLyse (Dako). Flow cytometry was performed using a FACSCanto TM II instrument with FACSDiva software (Becton Dickinson
Immunocytometry Systems, San Jose, CA). Platelet-leukocyte complexes and microparticles were defined and detected as previously described 7 . Determination of C3 or C9 deposition on platelet-leukocyte complexes and microparticles was performed using three-or four-color analysis for simultaneous detection of platelet-leukocyte complexes or microparticles, and C3 or C9. In phagocytosis experiments, neutrophils were selectively identified by appropriate settings of forward-and side scatter and measured for green fluorescence from associated BCECF-labeled microparticles.
Immunoblotting to detect C3 and C9 on microparticles
Microparticles were isolated from 1 mL of Stx2-or O157LPS-stimulated or unstimulated whole blood. Samples were diluted (1:10) and subjected to 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis under reducing conditions. Proteins were transferred onto equilibrated polyvinylidine difluoride membranes and blocked with casein solution (Vector Laboratories Inc, Burlingame, CA). Immunoblotting was performed with rabbit anti-human C3c (DAKO) or mouse anti-human iC3b followed by goat anti-rabbit HRP or goat anti-mouse HRP (DAKO), respectively. Signal was detected by chemiluminescence using ECL plus (Amersham Biosciences, Uppsala, Sweden).
Detection of C3a(desArg) or terminal complement complex in plasma
C3a(desArg) and human terminal complement complex (TCC) in plasma from patients or controls was quantified using a C3a assay kit or TCC kit (both from Hycult Biotech), following the manufacturer's instructions.
Alternatively, citrated whole blood (diluted 1:2 in RPMI1640) was stimulated with Stx2 or O157LPS or left unstimulated for 40 min at 37ºC and platelet-free-plasma obtained by centrifugation at 2000 x g for 15 min. Samples were stored at -80ºC until analyzed using the C3a(desArg) and TCC kits.
Statistical analysis
Comparison of blood cells incubated with the various agonists or unstimulated blood cells, generation of microparticles in stimulated or unstimulated whole blood, microparticles in patient plasma or control plasma, as well as C3 or C9 on complexes or microparticles were analyzed by the Mann-Whitney U-test. Correlations between clinical manifestations and 
Results
C3 bound to platelet-leukocyte complexes in a patient with HUS
Stx2, O157LPS and C3 deposition on circulating platelet-monocyte or platelet-neutrophil complexes ( Figure 1A -B) were measured in whole blood from one patient with E. coli O157:H7-associated HUS taken during the acute phase of disease (Patient 1 in Table 1 ) and compared to pediatric controls (n=5). C3 was detected by flow cytometry on 30% of plateletmonocyte complexes and 15% of platelet-neutrophil complexes during the acute phase of disease but decreased to 14% of platelet-monocyte complexes and 9% of platelet-neutrophil complexes after recovery, levels that were comparable with the pediatric controls ( Figure 1A -B). C9 was not determined on the patient's platelet-leukocyte complexes. Stx2 was detected on 15% of platelet-monocyte complexes and on 30% of platelet-neutrophil complexes.
Similarly, O157LPS was detected on 30% platelet-monocyte complexes and on 37% of platelet-neutrophil complexes. No binding of Stx2 or O157LPS was detected after recovery or in the pediatric controls.
Patients with HUS have increased levels of circulating microparticles with bound C3 and C9
Plasma levels of circulating microparticles with surface-bound C3 or C9 were measured by flow cytometry during the acute phase of disease and compared to pediatric controls (n=6) and patients with acute renal failure (n=3). Plasma taken during the acute phase showed significantly higher levels of circulating microparticles with surface-bound C3 and C9 (Table   2) Microparticles originated primarily from platelets followed by monocytes. Levels at recovery were similar to those found in the controls.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Laboratory findings (hemoglobin, platelet counts, creatinine, urea, dialysis (+ or -), C3 and C4 levels and extra-renal complications (+ or -), during the acute phase of HUS (Table 1) were correlated to levels of C3 and C9 on platelet-derived microparticles (10 3 /mL) and did not show a significant correlation (data not shown).
Patients with HUS had increased levels of C3a(desArg) and TCC in plasma
Plasma levels of C3a(desArg) and TCC were measured during the acute phase (n=10, patients 1-10) and after recovery and compared to pediatric controls (n=6). Levels were elevated during the acute phase of disease as presented in Table 3 .
Stx and O157LPS induce C3 and C9 deposition on platelet-leukocyte complexes
Incubation of whole blood with Stx2, Stx1 or Stx1B induced a significant increase in plateletmonocyte and platelet-neutrophil complexes with surface-bound C3 (Figure 2A 
Stx2-and/or O157LPS-stimulated whole blood induced complement activation via the alternative pathway
Whole blood diluted in RPMI/EDTA-VBS and stimulated with Stx2 and/or O157LPS exhibited marked reduction of surface-bound C3 or C9 on platelet-monocyte complexes (Table 4) . Whole blood diluted in RPMI/EGTA-VBS and stimulated with Stx2 and/or O157LPS exhibited slightly reduced surface-bound C3 and C9 on platelet-monocyte complexes compared to unstimulated whole blood diluted in RPMI alone. Inhibition experiments were not performed for platelet-neutrophil complexes. The results indicate that Stx2 and/or O157LPS activated complement mostly via the alternative pathway.
Blocking of Stx2 and/or O157LPS binding reduced platelet-monocyte complex formation and surface-bound C3 and C9
Incubation of whole blood with anti-Gb3 before incubation with Stx2 reduced plateletmonocyte complex formation significantly by 67%. Similarly, incubation of whole blood with anti-TLR4 before incubation with O157LPS reduced platelet-monocyte complex formation by 76% ( Figure 4A ). An even more prominent reduction by 80% was noted when whole blood was preincubated with both 
Stx and O157LPS induce release of microparticles with surface-bound C3 and C9
Levels of microparticles with surface-bound C3 or C9 were measured in whole blood stimulated with Stx2, Stx1, Stx1B, O157LPS or a combination of Stx2 and O157LPS. The agonists induced a significant increase in microparticles with surface-bound C3 or C9 compared to PBS-treated samples ( Table 5 ). The highest levels of microparticles were noted in whole blood co-stimulated with Stx2 and O157LPS compared to Stx2 or O157LPS alone.
The combination of Stx2 and O157LPS induced a significant increase in C3-and C9-positive microparticles derived from platelets, in comparison to each agonist alone.
Characterization of surface-bound C3 or C9 on platelets and platelet-derived microparticles
To further characterize surface-bound C3 on platelets and platelet-derived microparticles two monoclonal anti-C3 antibodies were used, one which binds to activated C3b and one which binds to iC3b. These antibodies specifically react with neoepitopes exposed in activated and conformationally altered C3 but not in native C3. Both antibodies bound to platelets and platelet-derived microparticles from Stx2-or O157LPS-stimulated whole blood ( Figure 5A and B) indicating that surface-bound C3 was activated C3b which was, to some extent, further processed to iC3b. The presence of C3 and iC3b on microparticles stimulated with Stx and Similarly, surface-bound C9 on platelets were characterized by use of two antibodies specifically reacting with the neoepitope in C9 (C9neo) or neoepitopes in the C5b-9 complex.
Both antibodies bound to the surface of platelets and platelet-derived microparticles ( Figure   5A and B) indicating formation of the membrane attack complex (MAC) on the surface of
and microparticles. O157LPS appeared to induce more deposition of C3b on platelets and platelet-derived microparticles than Stx2, although the difference was nonsignificant. Both stimulants induced significant C3 and C9 deposition compared to unstimulated platelets.
Microparticles express complement regulators on their surface
Expression of surface-bound complement regulators was examined on microparticles from O157LPS-stimulated whole blood. CR1 ( Figure 6A ), DAF ( Figure 6B ) and MCP ( Figure 6C) were detected on microparticles from platelets, monocytes and neutrophils and there was no significant difference between stimulated and unstimulated microparticles. 
Microparticles released in
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Stx and O157LPS induce C3a(desArg) and TCC release in whole blood
Levels of C3a(desArg) and TCC were measured in Stx2-or O157LPS-stimulated whole blood. Both Stx2 and O157LPS induced a significant increase in C3a(desArg) and TCC concentrations (Table 6) 
Discussion
This study demonstrates the presence of C3 on platelet-leukocyte complexes in a patient with EHEC-associated HUS. Activated leukocytes and platelets release microparticles during HUS, 7 and these blood cell-derived microparticles, particularly those originating from C3b binds to platelets via P selectin and to neutrophils and monocytes via complement receptor 1 (CR1). 12, 21 The opsonin iC3b binds to these cells via CR3 (the integrin receptor CD11b/CD18 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Platelet-and leukocyte-derived microparticles, which were coated with C3 and C9, underwent neutrophil phagocytosis. Complement-labeling is a well-studied phenomenon whereby opsonized bacteria undergo phagocytosis by professional phagocytes such as neutrophils, monocytes, macrophages and, to a lesser extent, dendritic cells. 29 iC3b is an important opsonin in this process. 30 Complement-coated microspheres undergo neutrophil phagocytosis. 31 The same process appears to occur when complement-coated microparticles are incubated with neutrophils, as shown here. This may represent a protective mechanism by which neutrophils ingest pro-coagulant microparticles to prevent excessive thrombosis.
The formation of the C5b-9 complex induces cytolysis, when present in high amounts, but in sublytic amounts cell activation is induced resulting in secretion of cytokines, prostanoids and free radicals. 17 ,32-34 C5b-9 assembly on platelets promotes the formation of the prothrombinase complex allowing generation of thrombin. 35 Thrombin and C5b-9 induce the exposure of negatively-charged phospholipids serving as a procoagulant surface on the platelet membrane 36 thus enabling clot formation. Interestingly, thrombin generation precedes the renal injury in HUS. 37 In the absence of C3, thrombin can function as a C5 convertase cleaving C5 38 and has therefore been suggested to induce C3-independent complement activation. 39 Thus, there appears to be cross-talk between the complement and thrombotic systems and C5b-9 deposition on blood cells may promote thrombus formation. This is further supported by the finding that complement C3 and C9 deposition on platelets induced their activation and release of tissue factor-bearing microparticles. 15 In vitro stimulation of blood cells with Stx and O157LPS lead to formation of blood-cell complexes bearing complement C3 and C9 suggesting that complement activation could occur on the cell surface even before membrane blebbing. We propose that the observed complement activation on blood cells may partake in the inflammatory process by enhanced opsonization and chemotaxis 40 as well as induce a prothrombotic state by enhancing platelet aggregation. 13 Stx is cytotoxic for most cells, but not for blood cells. 3, 41, 42 On the contrary, the life-span of neutrophils is extended by Stx. 43 The toxin has a stimulatory effect on platelets, monocytes and neutrophils. 3, 41, 44 Stx and O157LPS induced C3 and C9 deposition on platelets, monocytes and, to a lesser extent, neutrophils and even Stx1B alone induced complement deposition, indicating that toxin binding to its receptor was sufficient to induce C3 and C9
deposition. Stx and O157LPS may, however, not be the only underlying causes of complement deposition on blood cells during HUS as complement activation has been documented in other conditions associated with acute renal failure, most probably due to complement activation on dialysis membranes. 45 Most of the patients studied here did not, however, undergo hemodialysis. All the same we cannot exclude that Stx and O157LPS were not the only factors promoting complement activation and that inflammatory mediators and uremic toxins may have also contributed to the process.
Previous studies have shown that complement may be activated via the alternative pathway during EHEC-associated HUS. Patients were shown to have low levels of C3, 46 and elevated levels of complement factor Bb and sC5b-9. 47 Stx was reported to activate complement via the alternative pathway in the fluid phase, 48 and induce C3 deposition on human microvascular endothelial cells promoting thrombus formation. 4 Taken together with the results presented here, these studies indicate that complement may be activated via the alternative pathway during EHEC-associated HUS, which may promote disease-activity by further chemotaxis, tissue damage and platelet activation. The findings may have implications for future treatments because complement-inhibitors, such as the humanized anti-C5 antibody 49 Further studies are, however, required as the use of complement inhibitors during active infectious disease may pose a risk and postpone intestinal bacterial clearance.
In summary, this study provides evidence for complement activation on blood cells and blood cell-derived microparticles during EHEC-associated HUS, a process which could be related to contact between Stx and/or O157LPS and the blood cells as shown in vitro. This suggests that complement activation occurs in the circulation during HUS. Although complement activation is not the primary event occurring during EHEC infection, we speculate that it may contribute to blood cell activation and, via this cell activation and the release of microparticles, free radicals and cytokines, even to end-organ damage of the kidney in HUS. 
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